C. Russell Trenary III - Apr 17, 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
CEO and President, Director
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Apr 17, 2023
Transactions value $
$0
Form type
4
Date filed
4/19/2023, 05:40 PM
Previous filing
Jun 23, 2022
Next filing
Mar 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +257K $0.00 257K Apr 17, 2023 Common Stock 257K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.